| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 129 | 2024 | 2479 | 10.040 |
Why?
|
| Platelet Activation | 83 | 2024 | 645 | 9.260 |
Why?
|
| Platelet Aggregation | 57 | 2022 | 771 | 5.000 |
Why?
|
| Platelet Aggregation Inhibitors | 67 | 2022 | 2751 | 4.320 |
Why?
|
| Platelet Function Tests | 40 | 2021 | 271 | 4.060 |
Why?
|
| Ticlopidine | 28 | 2017 | 730 | 3.410 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 44 | 2021 | 577 | 3.290 |
Why?
|
| P-Selectin | 40 | 2021 | 597 | 2.510 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 21 | 2024 | 144 | 2.480 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 7 | 2018 | 242 | 2.450 |
Why?
|
| Platelet Membrane Glycoproteins | 33 | 2016 | 284 | 2.250 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 178 | 2.150 |
Why?
|
| Flow Cytometry | 55 | 2021 | 5869 | 1.760 |
Why?
|
| Aspirin | 29 | 2021 | 3133 | 1.680 |
Why?
|
| Platelet Count | 11 | 2021 | 781 | 1.650 |
Why?
|
| Serotonin | 4 | 2024 | 1041 | 1.620 |
Why?
|
| Adenosine Diphosphate | 23 | 2016 | 422 | 1.550 |
Why?
|
| Thrombin | 26 | 2021 | 591 | 1.410 |
Why?
|
| Drug Resistance | 17 | 2009 | 1596 | 1.410 |
Why?
|
| Purinergic P2 Receptor Antagonists | 6 | 2011 | 67 | 1.380 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 154 | 1.280 |
Why?
|
| Thrombosis | 29 | 2024 | 2942 | 1.280 |
Why?
|
| Fibrinolytic Agents | 17 | 2019 | 2084 | 1.260 |
Why?
|
| Sudden Infant Death | 2 | 2024 | 292 | 1.220 |
Why?
|
| Thiophenes | 8 | 2018 | 569 | 1.220 |
Why?
|
| Electricity | 3 | 2021 | 181 | 1.200 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 701 | 1.160 |
Why?
|
| Thrombocytopenia | 10 | 2021 | 1181 | 1.160 |
Why?
|
| Receptors, Purinergic P2Y12 | 15 | 2018 | 115 | 1.120 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 8 | 2018 | 284 | 1.030 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 161 | 1.000 |
Why?
|
| Hemorrhage | 14 | 2022 | 3424 | 0.950 |
Why?
|
| CD40 Ligand | 7 | 2021 | 522 | 0.950 |
Why?
|
| Blood Platelet Disorders | 6 | 2021 | 60 | 0.890 |
Why?
|
| Angioplasty, Balloon, Coronary | 15 | 2009 | 1725 | 0.870 |
Why?
|
| 14-3-3 Proteins | 1 | 2024 | 220 | 0.850 |
Why?
|
| Gray Platelet Syndrome | 4 | 2020 | 7 | 0.850 |
Why?
|
| Piperazines | 9 | 2013 | 2523 | 0.850 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 32 | 0.830 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 618 | 0.810 |
Why?
|
| Leukocytes | 8 | 2016 | 2026 | 0.780 |
Why?
|
| Monocytes | 11 | 2015 | 2570 | 0.780 |
Why?
|
| Immunoglobulin Fab Fragments | 11 | 2013 | 445 | 0.770 |
Why?
|
| Acute Coronary Syndrome | 12 | 2015 | 2190 | 0.690 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2021 | 1651 | 0.660 |
Why?
|
| Factor V | 3 | 2008 | 167 | 0.640 |
Why?
|
| Anemia, Sickle Cell | 5 | 2022 | 1063 | 0.630 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1154 | 0.630 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 72 | 0.620 |
Why?
|
| Hematologic Agents | 1 | 2018 | 40 | 0.610 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 97 | 0.600 |
Why?
|
| Hemophilia A | 1 | 2021 | 360 | 0.580 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 40 | 0.570 |
Why?
|
| Coronary Thrombosis | 5 | 2018 | 440 | 0.570 |
Why?
|
| Pyrazoles | 5 | 2019 | 2009 | 0.570 |
Why?
|
| Blood Specimen Collection | 3 | 2016 | 238 | 0.560 |
Why?
|
| Factor Va | 3 | 2021 | 10 | 0.560 |
Why?
|
| Asphyxia | 1 | 2017 | 60 | 0.560 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 165 | 0.550 |
Why?
|
| Drug Monitoring | 5 | 2021 | 962 | 0.550 |
Why?
|
| Coronary Disease | 10 | 2007 | 5914 | 0.550 |
Why?
|
| Hemostasis | 5 | 2024 | 467 | 0.540 |
Why?
|
| Receptors, Thrombin | 8 | 2022 | 130 | 0.530 |
Why?
|
| Receptor, PAR-1 | 5 | 2021 | 109 | 0.520 |
Why?
|
| Humans | 232 | 2024 | 761504 | 0.510 |
Why?
|
| Cardiovascular Diseases | 17 | 2020 | 15500 | 0.490 |
Why?
|
| Hemoglobins | 1 | 2021 | 1525 | 0.490 |
Why?
|
| Microfilament Proteins | 4 | 2017 | 1134 | 0.480 |
Why?
|
| Benzoates | 2 | 2015 | 212 | 0.460 |
Why?
|
| Hydrazines | 2 | 2015 | 224 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 30 | 2013 | 9177 | 0.440 |
Why?
|
| Neutrophils | 9 | 2022 | 3767 | 0.430 |
Why?
|
| Proton Pump Inhibitors | 3 | 2013 | 532 | 0.410 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1394 | 0.400 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 188 | 0.400 |
Why?
|
| Cell Degranulation | 5 | 1998 | 277 | 0.400 |
Why?
|
| Thromboembolism | 6 | 2019 | 995 | 0.390 |
Why?
|
| Omeprazole | 1 | 2012 | 105 | 0.380 |
Why?
|
| Polymorphism, Genetic | 4 | 2017 | 4243 | 0.380 |
Why?
|
| Cytoplasmic Granules | 5 | 2022 | 574 | 0.370 |
Why?
|
| Thiazoles | 1 | 2018 | 1517 | 0.370 |
Why?
|
| Heparin, Low-Molecular-Weight | 4 | 2008 | 344 | 0.360 |
Why?
|
| Cell Adhesion Molecules | 6 | 2017 | 1600 | 0.350 |
Why?
|
| Thromboxane B2 | 5 | 2015 | 143 | 0.350 |
Why?
|
| Dogs | 6 | 2018 | 3839 | 0.350 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 23 | 0.340 |
Why?
|
| Liver Diseases | 1 | 2018 | 1298 | 0.340 |
Why?
|
| Venous Insufficiency | 2 | 2002 | 108 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 20 | 2018 | 10766 | 0.340 |
Why?
|
| Thrombasthenia | 5 | 2018 | 21 | 0.340 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 145 | 0.330 |
Why?
|
| Male | 91 | 2024 | 360804 | 0.320 |
Why?
|
| Cell Separation | 3 | 2005 | 1720 | 0.320 |
Why?
|
| Coronary Artery Disease | 10 | 2016 | 6403 | 0.310 |
Why?
|
| Chest Pain | 2 | 2014 | 1091 | 0.310 |
Why?
|
| Clot Retraction | 1 | 2007 | 13 | 0.300 |
Why?
|
| Immunophenotyping | 4 | 2021 | 1870 | 0.300 |
Why?
|
| Cystic Fibrosis | 3 | 2007 | 1285 | 0.300 |
Why?
|
| Vascular Patency | 3 | 2009 | 911 | 0.290 |
Why?
|
| Arachidonic Acid | 2 | 2006 | 427 | 0.290 |
Why?
|
| Tyrosine | 2 | 2003 | 1440 | 0.290 |
Why?
|
| Heparin | 7 | 2004 | 1634 | 0.290 |
Why?
|
| Fibrinogen | 7 | 2015 | 888 | 0.290 |
Why?
|
| Cathepsins | 4 | 2001 | 241 | 0.290 |
Why?
|
| Thrombophilia | 1 | 2010 | 305 | 0.280 |
Why?
|
| Nitric Oxide | 6 | 2000 | 2135 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2021 | 3810 | 0.280 |
Why?
|
| Female | 83 | 2024 | 392644 | 0.280 |
Why?
|
| Epinephrine | 8 | 2008 | 792 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3613 | 0.270 |
Why?
|
| Morpholines | 1 | 2009 | 581 | 0.270 |
Why?
|
| Blood Coagulation Factors | 2 | 2007 | 365 | 0.260 |
Why?
|
| Prodrugs | 1 | 2007 | 261 | 0.260 |
Why?
|
| Thromboxane A2 | 6 | 2008 | 88 | 0.250 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 1265 | 0.250 |
Why?
|
| Phosphoproteins | 3 | 2017 | 2448 | 0.250 |
Why?
|
| Dalteparin | 2 | 2003 | 44 | 0.250 |
Why?
|
| Peptide Fragments | 9 | 2015 | 5112 | 0.250 |
Why?
|
| Contrast Media | 5 | 1996 | 5311 | 0.240 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2015 | 131 | 0.240 |
Why?
|
| Middle Aged | 52 | 2021 | 220895 | 0.240 |
Why?
|
| Myocardial Infarction | 8 | 2010 | 11460 | 0.230 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2018 | 214 | 0.230 |
Why?
|
| Hypothermia, Induced | 2 | 2003 | 753 | 0.230 |
Why?
|
| Benzamides | 1 | 2009 | 1370 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 597 | 0.220 |
Why?
|
| Endothelium, Vascular | 4 | 2016 | 4431 | 0.220 |
Why?
|
| Double-Blind Method | 13 | 2019 | 12341 | 0.220 |
Why?
|
| Adult | 53 | 2021 | 221177 | 0.220 |
Why?
|
| Infant, Newborn | 15 | 2024 | 26198 | 0.220 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 6310 | 0.220 |
Why?
|
| Thrombelastography | 3 | 2018 | 187 | 0.220 |
Why?
|
| Drug Interactions | 6 | 2014 | 1416 | 0.210 |
Why?
|
| Laboratories | 1 | 2007 | 458 | 0.210 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2013 | 244 | 0.210 |
Why?
|
| Antigens, CD | 6 | 2003 | 4003 | 0.210 |
Why?
|
| Acute Chest Syndrome | 1 | 2022 | 32 | 0.210 |
Why?
|
| von Willebrand Factor | 9 | 2000 | 673 | 0.200 |
Why?
|
| Child | 29 | 2022 | 80153 | 0.200 |
Why?
|
| Exocytosis | 2 | 2015 | 320 | 0.200 |
Why?
|
| Angina, Unstable | 2 | 2004 | 888 | 0.200 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2014 | 322 | 0.200 |
Why?
|
| Cell Aggregation | 4 | 2005 | 239 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2015 | 103 | 0.200 |
Why?
|
| Platelet Transfusion | 5 | 2011 | 297 | 0.200 |
Why?
|
| Case-Control Studies | 13 | 2020 | 22176 | 0.190 |
Why?
|
| Fibrinolysis | 4 | 1996 | 332 | 0.190 |
Why?
|
| Cell Adhesion | 3 | 2003 | 3087 | 0.190 |
Why?
|
| Collagen | 5 | 2009 | 2638 | 0.190 |
Why?
|
| Area Under Curve | 3 | 2022 | 1638 | 0.190 |
Why?
|
| Child, Preschool | 21 | 2022 | 42230 | 0.190 |
Why?
|
| Varicose Ulcer | 2 | 1999 | 55 | 0.190 |
Why?
|
| Infant | 16 | 2024 | 36192 | 0.190 |
Why?
|
| Gaucher Disease | 1 | 2021 | 110 | 0.180 |
Why?
|
| Image Cytometry | 1 | 2001 | 54 | 0.180 |
Why?
|
| Thrombolytic Therapy | 3 | 2007 | 2064 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1844 | 0.180 |
Why?
|
| Varicose Veins | 1 | 2002 | 155 | 0.180 |
Why?
|
| Venous Thrombosis | 2 | 2008 | 1303 | 0.180 |
Why?
|
| Calgranulin A | 1 | 2021 | 80 | 0.180 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 4853 | 0.180 |
Why?
|
| Blood Preservation | 5 | 2005 | 168 | 0.180 |
Why?
|
| Calgranulin B | 1 | 2021 | 86 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2019 | 10209 | 0.180 |
Why?
|
| Cross-Over Studies | 5 | 2013 | 2078 | 0.170 |
Why?
|
| Blood Cell Count | 1 | 2021 | 397 | 0.170 |
Why?
|
| Treatment Outcome | 24 | 2020 | 64680 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 1779 | 0.170 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 389 | 0.170 |
Why?
|
| Integrin beta3 | 4 | 2018 | 120 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1736 | 0.170 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 48 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 857 | 0.160 |
Why?
|
| Neutrophil Activation | 1 | 1999 | 180 | 0.160 |
Why?
|
| Receptors, Cell Surface | 4 | 1994 | 2822 | 0.160 |
Why?
|
| Factor VIII | 1 | 2021 | 348 | 0.160 |
Why?
|
| Fibrinolysin | 6 | 1995 | 131 | 0.160 |
Why?
|
| Stroke | 5 | 2021 | 9757 | 0.160 |
Why?
|
| Phenotype | 5 | 2020 | 16591 | 0.150 |
Why?
|
| Animals | 38 | 2022 | 168459 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1866 | 0.150 |
Why?
|
| Time Factors | 15 | 2018 | 39967 | 0.150 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 396 | 0.150 |
Why?
|
| Calcium | 5 | 2021 | 5722 | 0.150 |
Why?
|
| Papio | 7 | 2005 | 669 | 0.150 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 94 | 0.150 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 5 | 1997 | 58 | 0.150 |
Why?
|
| Dog Diseases | 1 | 2018 | 141 | 0.150 |
Why?
|
| Reference Values | 4 | 2012 | 4920 | 0.150 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 93 | 0.150 |
Why?
|
| Membrane Proteins | 7 | 2012 | 7856 | 0.140 |
Why?
|
| Anticoagulants | 7 | 2022 | 4812 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 233 | 0.140 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 732 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 695 | 0.140 |
Why?
|
| Fontan Procedure | 2 | 2022 | 796 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2018 | 385 | 0.130 |
Why?
|
| Bleeding Time | 5 | 2011 | 83 | 0.130 |
Why?
|
| Ioxaglic Acid | 4 | 1996 | 29 | 0.130 |
Why?
|
| Antifibrinolytic Agents | 2 | 1996 | 292 | 0.130 |
Why?
|
| Cattle | 3 | 2019 | 3849 | 0.130 |
Why?
|
| Premedication | 1 | 1996 | 246 | 0.130 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 973 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 77 | 0.130 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 324 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1541 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2014 | 7879 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2006 | 3049 | 0.120 |
Why?
|
| Immune System | 1 | 2020 | 796 | 0.120 |
Why?
|
| Cytoskeleton | 3 | 1996 | 1170 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 1999 | 417 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1971 | 0.120 |
Why?
|
| Freeze Drying | 2 | 2005 | 101 | 0.120 |
Why?
|
| Thromboplastin | 2 | 2007 | 286 | 0.120 |
Why?
|
| Cell Line | 4 | 2021 | 15601 | 0.120 |
Why?
|
| Partial Thromboplastin Time | 2 | 2022 | 204 | 0.120 |
Why?
|
| Risk Factors | 11 | 2021 | 74206 | 0.120 |
Why?
|
| Hearing Loss, Sudden | 1 | 1995 | 45 | 0.120 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1997 | 407 | 0.120 |
Why?
|
| Purinergic Antagonists | 1 | 2014 | 10 | 0.120 |
Why?
|
| Aged | 24 | 2021 | 169289 | 0.110 |
Why?
|
| Genotype | 6 | 2017 | 12990 | 0.110 |
Why?
|
| Oligopeptides | 3 | 1996 | 1187 | 0.110 |
Why?
|
| Blood Loss, Surgical | 2 | 1999 | 637 | 0.110 |
Why?
|
| Vitamin K | 2 | 2008 | 318 | 0.110 |
Why?
|
| Adenosine | 2 | 2017 | 808 | 0.110 |
Why?
|
| Aprotinin | 1 | 1993 | 94 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 490 | 0.110 |
Why?
|
| Autopsy | 1 | 2017 | 1008 | 0.110 |
Why?
|
| Predictive Value of Tests | 6 | 2010 | 15266 | 0.110 |
Why?
|
| Adolescent | 14 | 2021 | 88319 | 0.110 |
Why?
|
| Kinetics | 6 | 2017 | 6374 | 0.110 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 450 | 0.110 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cathepsin G | 4 | 2001 | 31 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 1996 | 415 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1999 | 1092 | 0.100 |
Why?
|
| Treatment Refusal | 2 | 2006 | 429 | 0.100 |
Why?
|
| Heart Diseases | 3 | 2014 | 2781 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2019 | 1336 | 0.100 |
Why?
|
| R-SNARE Proteins | 1 | 2012 | 75 | 0.100 |
Why?
|
| Macrophage-1 Antigen | 2 | 2005 | 285 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 1551 | 0.100 |
Why?
|
| Biotin | 3 | 2005 | 254 | 0.100 |
Why?
|
| Vestibular Diseases | 1 | 1995 | 230 | 0.100 |
Why?
|
| Brain Stem | 1 | 2017 | 858 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 432 | 0.100 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 3 | 1997 | 65 | 0.100 |
Why?
|
| Triiodobenzoic Acids | 3 | 1996 | 123 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1353 | 0.100 |
Why?
|
| Glycogen Synthase | 1 | 1991 | 62 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10445 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 386 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2018 | 3702 | 0.090 |
Why?
|
| Cyclic GMP | 3 | 1997 | 395 | 0.090 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 2 | 2018 | 51 | 0.090 |
Why?
|
| Inflammation | 7 | 2022 | 10773 | 0.090 |
Why?
|
| Polyurethanes | 1 | 1991 | 109 | 0.090 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2005 | 130 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 220 | 0.090 |
Why?
|
| Recurrence | 3 | 2009 | 8465 | 0.090 |
Why?
|
| Iohexol | 3 | 1996 | 204 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 2898 | 0.090 |
Why?
|
| Down-Regulation | 3 | 1994 | 2919 | 0.090 |
Why?
|
| Peptides | 3 | 2013 | 4358 | 0.090 |
Why?
|
| Cell Shape | 1 | 2011 | 371 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 26125 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2018 | 9318 | 0.090 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 13 | 0.090 |
Why?
|
| Edetic Acid | 2 | 2004 | 280 | 0.090 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 11 | 0.090 |
Why?
|
| Models, Biological | 3 | 2022 | 9469 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 803 | 0.090 |
Why?
|
| Amino Acid Sequence | 7 | 2001 | 13446 | 0.090 |
Why?
|
| Tissue Fixation | 2 | 2001 | 241 | 0.080 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 64 | 0.080 |
Why?
|
| Glycoproteins | 4 | 2002 | 2203 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 3 | 1995 | 1164 | 0.080 |
Why?
|
| Epoprostenol | 3 | 1996 | 247 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2011 | 190 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2811 | 0.080 |
Why?
|
| Pain | 2 | 2022 | 5073 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1462 | 0.080 |
Why?
|
| Endothelium | 2 | 2003 | 765 | 0.080 |
Why?
|
| Signal Transduction | 7 | 2020 | 23445 | 0.080 |
Why?
|
| Acute Disease | 3 | 2006 | 7237 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.080 |
Why?
|
| Cell Membrane | 4 | 2015 | 3688 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2021 | 284 | 0.080 |
Why?
|
| Syndrome | 2 | 2006 | 3267 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 8002 | 0.080 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1213 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 817 | 0.080 |
Why?
|
| Glutathione Peroxidase | 3 | 2000 | 258 | 0.080 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 83 | 0.080 |
Why?
|
| Leukocyte Elastase | 2 | 2001 | 114 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1287 | 0.080 |
Why?
|
| Cells, Cultured | 6 | 2015 | 18965 | 0.080 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2021 | 4021 | 0.070 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 212 | 0.070 |
Why?
|
| Biotransformation | 1 | 2007 | 166 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 12148 | 0.070 |
Why?
|
| Sepsis | 1 | 2022 | 2585 | 0.070 |
Why?
|
| Prospective Studies | 9 | 2022 | 54425 | 0.070 |
Why?
|
| Coronary Angiography | 2 | 2015 | 4471 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2019 | 3028 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3492 | 0.070 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2008 | 150 | 0.070 |
Why?
|
| Infant, Premature | 1 | 1997 | 2107 | 0.070 |
Why?
|
| Erythema | 1 | 1989 | 262 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2017 | 2911 | 0.070 |
Why?
|
| Communication | 1 | 2021 | 3873 | 0.070 |
Why?
|
| Serine Endopeptidases | 4 | 2001 | 1022 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2001 | 17635 | 0.070 |
Why?
|
| Diatrizoate | 2 | 1996 | 81 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 613 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 15936 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2016 | 2331 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11528 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.070 |
Why?
|
| Borrelia Infections | 2 | 2003 | 17 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2019 | 15631 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 69 | 0.070 |
Why?
|
| Cell Communication | 2 | 2022 | 1657 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2005 | 3627 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2927 | 0.070 |
Why?
|
| Cryopreservation | 3 | 2004 | 728 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1569 | 0.070 |
Why?
|
| Angina Pectoris | 2 | 2002 | 959 | 0.070 |
Why?
|
| Thalassemia | 1 | 1987 | 267 | 0.070 |
Why?
|
| Protein Binding | 6 | 2003 | 9351 | 0.070 |
Why?
|
| Risk Assessment | 6 | 2021 | 23995 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2010 | 617 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2273 | 0.060 |
Why?
|
| Research | 1 | 2014 | 1982 | 0.060 |
Why?
|
| Young Adult | 9 | 2021 | 59243 | 0.060 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18252 | 0.060 |
Why?
|
| Oxyquinoline | 1 | 2005 | 16 | 0.060 |
Why?
|
| Blood Cells | 1 | 2007 | 305 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 883 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2013 | 8320 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2805 | 0.060 |
Why?
|
| Alprostadil | 1 | 2005 | 86 | 0.060 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 168 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3415 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 931 | 0.060 |
Why?
|
| Destrin | 1 | 2004 | 10 | 0.060 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 231 | 0.060 |
Why?
|
| Relapsing Fever | 2 | 2003 | 24 | 0.060 |
Why?
|
| Solubility | 2 | 2004 | 1091 | 0.060 |
Why?
|
| Cytochalasin D | 1 | 2004 | 91 | 0.060 |
Why?
|
| Drug Design | 1 | 2010 | 1048 | 0.060 |
Why?
|
| Factor Xa | 1 | 2005 | 167 | 0.060 |
Why?
|
| Heterozygote | 2 | 2011 | 2787 | 0.060 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 42 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 1987 | 694 | 0.060 |
Why?
|
| Toxoplasmosis | 1 | 1984 | 94 | 0.060 |
Why?
|
| Chemokines | 1 | 2008 | 960 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 110 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1702 | 0.060 |
Why?
|
| Spirochaetales | 1 | 2003 | 26 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2012 | 3429 | 0.060 |
Why?
|
| Gene Expression | 2 | 2015 | 7581 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2006 | 365 | 0.060 |
Why?
|
| Consensus | 2 | 2021 | 3123 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 1984 | 162 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2006 | 3688 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2005 | 229 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1990 | 1741 | 0.050 |
Why?
|
| Pseudopodia | 2 | 2015 | 168 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3673 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 481 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2007 | 4124 | 0.050 |
Why?
|
| Case Management | 1 | 2004 | 272 | 0.050 |
Why?
|
| Methods | 1 | 2003 | 1067 | 0.050 |
Why?
|
| Hemostatics | 2 | 2003 | 241 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2004 | 387 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 382 | 0.050 |
Why?
|
| Blood | 2 | 2003 | 596 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 1474 | 0.050 |
Why?
|
| Fibrin | 2 | 2016 | 507 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 1738 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 823 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2690 | 0.050 |
Why?
|
| Binding Sites | 5 | 2002 | 6055 | 0.050 |
Why?
|
| Exercise | 3 | 2011 | 5890 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 6484 | 0.050 |
Why?
|
| Dipeptides | 1 | 2004 | 391 | 0.050 |
Why?
|
| Mitochondria | 1 | 1995 | 3624 | 0.050 |
Why?
|
| Actins | 3 | 1996 | 2050 | 0.050 |
Why?
|
| Insulin | 2 | 2019 | 6596 | 0.050 |
Why?
|
| Atherectomy | 1 | 2001 | 42 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2022 | 117 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 393 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2019 | 10090 | 0.050 |
Why?
|
| Wounds and Injuries | 2 | 1992 | 2491 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2022 | 208 | 0.050 |
Why?
|
| Placebos | 2 | 2018 | 1667 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1896 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 202 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3617 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 73 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 981 | 0.050 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 3 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2021 | 159 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1463 | 0.050 |
Why?
|
| Age Factors | 3 | 2011 | 18395 | 0.050 |
Why?
|
| Borrelia | 1 | 2001 | 66 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 3396 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 754 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 243 | 0.040 |
Why?
|
| Anemia, Aplastic | 1 | 1982 | 230 | 0.040 |
Why?
|
| Hirudins | 1 | 2001 | 179 | 0.040 |
Why?
|
| Vitamin E | 1 | 2005 | 872 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2020 | 41487 | 0.040 |
Why?
|
| Fluorescent Dyes | 2 | 2000 | 1903 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2001 | 1141 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 462 | 0.040 |
Why?
|
| Prognosis | 4 | 2008 | 29625 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2005 | 536 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2576 | 0.040 |
Why?
|
| Data Collection | 1 | 2009 | 3322 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 2000 | 532 | 0.040 |
Why?
|
| Androstadienes | 2 | 1999 | 348 | 0.040 |
Why?
|
| Receptors, Purinergic P2X | 2 | 2009 | 9 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2003 | 559 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8540 | 0.040 |
Why?
|
| Plateletpheresis | 1 | 1999 | 38 | 0.040 |
Why?
|
| Blood Banks | 1 | 2000 | 108 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2001 | 685 | 0.040 |
Why?
|
| Mice | 10 | 2022 | 81525 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 1408 | 0.040 |
Why?
|
| Heparinoids | 1 | 1998 | 7 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2009 | 4159 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2002 | 1813 | 0.040 |
Why?
|
| Aging | 2 | 1995 | 8708 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2000 | 248 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 306 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2330 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 497 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 1999 | 126 | 0.040 |
Why?
|
| Tissue Preservation | 1 | 1999 | 174 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2020 | 256 | 0.040 |
Why?
|
| Genistein | 1 | 1998 | 86 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1475 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2219 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 675 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2019 | 8631 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2002 | 1755 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1875 | 0.040 |
Why?
|
| Saphenous Vein | 2 | 2003 | 516 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 4671 | 0.040 |
Why?
|
| Calibration | 1 | 2000 | 818 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4575 | 0.040 |
Why?
|
| Quality Control | 1 | 2000 | 832 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2005 | 5035 | 0.040 |
Why?
|
| Granulocytes | 1 | 1999 | 551 | 0.040 |
Why?
|
| Stents | 3 | 2008 | 3179 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2471 | 0.040 |
Why?
|
| Uremia | 1 | 1998 | 201 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 520 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2002 | 702 | 0.040 |
Why?
|
| Staurosporine | 1 | 1998 | 242 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1997 | 260 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2005 | 1808 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 20098 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2001 | 1687 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2001 | 3968 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 12059 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 1923 | 0.030 |
Why?
|
| E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
| Cell Survival | 3 | 2005 | 5791 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 1991 | 4486 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14666 | 0.030 |
Why?
|
| Antigens, Human Platelet | 1 | 1996 | 41 | 0.030 |
Why?
|
| Pedigree | 2 | 2021 | 4542 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 11076 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1997 | 306 | 0.030 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1987 | 1666 | 0.030 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 24 | 0.030 |
Why?
|
| Smoking | 1 | 2013 | 9053 | 0.030 |
Why?
|
| Pancreatic Elastase | 1 | 1996 | 127 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2003 | 1250 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 1996 | 210 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2000 | 1217 | 0.030 |
Why?
|
| Drug Stability | 1 | 2015 | 291 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4465 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2020 | 1173 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1996 | 384 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1996 | 223 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3076 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3093 | 0.030 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1994 | 8 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2001 | 2048 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 1996 | 260 | 0.030 |
Why?
|
| United States | 3 | 2018 | 72334 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2012 | 1347 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 1995 | 238 | 0.030 |
Why?
|
| Vestibular Function Tests | 1 | 1995 | 128 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2002 | 1646 | 0.030 |
Why?
|
| Cytochromes | 1 | 2014 | 18 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 908 | 0.030 |
Why?
|
| Cell Size | 1 | 1996 | 624 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 3 | 2008 | 7390 | 0.030 |
Why?
|
| beta-Thromboglobulin | 1 | 1993 | 20 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 160 | 0.030 |
Why?
|
| Mutation | 4 | 2021 | 30052 | 0.030 |
Why?
|
| Cell Count | 1 | 1998 | 1835 | 0.030 |
Why?
|
| Peptidoglycan | 1 | 1995 | 249 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3606 | 0.030 |
Why?
|
| Antithrombin III | 1 | 1993 | 128 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1993 | 337 | 0.030 |
Why?
|
| Meniere Disease | 1 | 1995 | 164 | 0.030 |
Why?
|
| Auditory Threshold | 1 | 1995 | 369 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2014 | 614 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4352 | 0.030 |
Why?
|
| Vesicle-Associated Membrane Protein 3 | 1 | 2012 | 12 | 0.030 |
Why?
|
| Vestibule, Labyrinth | 1 | 1995 | 234 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 1996 | 730 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 58976 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 2561 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1705 | 0.020 |
Why?
|
| Phosphorylases | 1 | 1991 | 17 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2020 | 1051 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4278 | 0.020 |
Why?
|
| Coronary Vessels | 2 | 2006 | 3096 | 0.020 |
Why?
|
| Carbazoles | 1 | 2013 | 220 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 983 | 0.020 |
Why?
|
| Patient Selection | 3 | 2008 | 4244 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2013 | 238 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1993 | 422 | 0.020 |
Why?
|
| Cytochalasin B | 1 | 1991 | 74 | 0.020 |
Why?
|
| Fibronectins | 1 | 2015 | 723 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 12974 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 143 | 0.020 |
Why?
|
| Progesterone Congeners | 1 | 2011 | 44 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Serratia marcescens | 1 | 1991 | 46 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2735 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 1994 | 654 | 0.020 |
Why?
|
| Ristocetin | 4 | 1998 | 26 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 1993 | 624 | 0.020 |
Why?
|
| Program Development | 1 | 1997 | 1297 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1334 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 560 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12795 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 623 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 2865 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1596 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1188 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 1749 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2013 | 566 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 12947 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1998 | 1797 | 0.020 |
Why?
|
| Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15842 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 541 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1171 | 0.020 |
Why?
|
| Centrifugation | 1 | 1988 | 122 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 781 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 1998 | 1553 | 0.020 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 1987 | 7 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3579 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 678 | 0.020 |
Why?
|
| Incidence | 2 | 2021 | 21353 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 95 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 771 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3712 | 0.020 |
Why?
|
| Endopeptidases | 1 | 1991 | 774 | 0.020 |
Why?
|
| Patient Admission | 1 | 1995 | 1367 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3085 | 0.020 |
Why?
|
| Arteries | 1 | 2012 | 1123 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1776 | 0.020 |
Why?
|
| Pyridines | 2 | 2009 | 2875 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2012 | 22169 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 1967 | 0.020 |
Why?
|
| Reticulocytes | 1 | 1987 | 289 | 0.020 |
Why?
|
| Maryland | 1 | 2006 | 277 | 0.020 |
Why?
|
| Monosaccharides | 1 | 1986 | 68 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1987 | 510 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1989 | 13639 | 0.020 |
Why?
|
| Cell Movement | 1 | 1998 | 5203 | 0.020 |
Why?
|
| Exercise Test | 1 | 1993 | 2127 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 1682 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 1986 | 135 | 0.020 |
Why?
|
| Carbohydrate Sequence | 1 | 1986 | 411 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2850 | 0.020 |
Why?
|
| Succinimides | 1 | 2005 | 81 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3416 | 0.010 |
Why?
|
| Temperature | 1 | 2011 | 2226 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14605 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8181 | 0.010 |
Why?
|
| Pyrimethamine | 1 | 1984 | 94 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16981 | 0.010 |
Why?
|
| Epitopes | 1 | 1991 | 2503 | 0.010 |
Why?
|
| Polysomnography | 1 | 2011 | 1848 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2013 | 2555 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1984 | 189 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2011 | 834 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2571 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6075 | 0.010 |
Why?
|
| Transfection | 2 | 2002 | 5774 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3548 | 0.010 |
Why?
|
| Research Design | 1 | 2019 | 6180 | 0.010 |
Why?
|
| Cardiology | 1 | 2014 | 1656 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9646 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2414 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1988 | 686 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5247 | 0.010 |
Why?
|
| Isoleucine | 1 | 2002 | 110 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1371 | 0.010 |
Why?
|
| Rabbits | 1 | 2008 | 4772 | 0.010 |
Why?
|
| Static Electricity | 1 | 2002 | 261 | 0.010 |
Why?
|
| Alleles | 1 | 2013 | 6863 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2395 | 0.010 |
Why?
|
| Antigens | 1 | 1987 | 1443 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1860 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 2005 | 647 | 0.010 |
Why?
|
| Sinusitis | 1 | 1990 | 991 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2176 | 0.010 |
Why?
|
| Valine | 1 | 2002 | 408 | 0.010 |
Why?
|
| Comorbidity | 1 | 2015 | 10508 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1990 | 6534 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2001 | 169 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 1458 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4425 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1982 | 852 | 0.010 |
Why?
|
| Equipment Design | 1 | 2008 | 3510 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2001 | 393 | 0.010 |
Why?
|
| Rats | 1 | 2015 | 23742 | 0.010 |
Why?
|
| Pediatrics | 1 | 2014 | 3589 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 128 | 0.010 |
Why?
|
| Heart | 1 | 2012 | 4404 | 0.010 |
Why?
|
| Culture Media | 1 | 2001 | 897 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2002 | 1232 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 2626 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 1387 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 1003 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2220 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 1998 | 159 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 2423 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9486 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 2469 | 0.010 |
Why?
|
| Glutathione | 1 | 1999 | 583 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 1999 | 535 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4481 | 0.010 |
Why?
|
| Plasma | 1 | 1999 | 586 | 0.010 |
Why?
|
| Observer Variation | 1 | 2002 | 2606 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8481 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8529 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 2416 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12725 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39106 | 0.010 |
Why?
|
| Streptokinase | 2 | 1985 | 186 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 5492 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 12463 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13255 | 0.010 |
Why?
|
| Family Health | 1 | 1999 | 1257 | 0.010 |
Why?
|
| Kidney | 1 | 2010 | 7048 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 1379 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2000 | 2231 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 12953 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13506 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 5439 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2006 | 80636 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5871 | 0.010 |
Why?
|
| Lung | 1 | 1990 | 10000 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 12441 | 0.010 |
Why?
|
| Causality | 1 | 1998 | 1242 | 0.010 |
Why?
|
| Asthma | 1 | 1990 | 6234 | 0.010 |
Why?
|
| Plethysmography, Whole Body | 1 | 1990 | 25 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 4544 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 1990 | 216 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1990 | 379 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 7212 | 0.010 |
Why?
|
| Paranasal Sinuses | 1 | 1990 | 265 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17904 | 0.000 |
Why?
|
| Formaldehyde | 1 | 1985 | 358 | 0.000 |
Why?
|
| Isoantigens | 1 | 1985 | 551 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 2186 | 0.000 |
Why?
|
| Lysine | 1 | 1986 | 993 | 0.000 |
Why?
|